A61K31/4458

Hydrogel polymeric compositions and methods

Some aspects of this disclosure relate to a method of treating an opthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent.

Delayed Release Methylphenidate Compositions

The present disclosure provides programmable osmotic-controlled oral compositions providing delayed extended release of a therapeutically acceptable amount of methylphenidate hydrochloride. The programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, and volume of gastric fluid. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm that matches the circadian rhythm of an individual being treated to optimize therapeutic outcome and minimize side effects.

Delayed Release Methylphenidate Compositions

The present disclosure provides programmable osmotic-controlled oral compositions providing delayed extended release of a therapeutically acceptable amount of methylphenidate hydrochloride. The programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, and volume of gastric fluid. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm that matches the circadian rhythm of an individual being treated to optimize therapeutic outcome and minimize side effects.

COMBINING ELECTRONIC MONITORING WITH INHALED PHARMACOLOGICAL THERAPY TO MANAGE CARDIAC ARRHYTHMIAS INCLUDING ATRIAL FIBRILLATION

Disclosed herein are methods of treating cardiac arrhythmia with electronic monitoring in a timely manner. Also disclosed herein are systems for electronic monitoring of cardiac arrhythmia.

COMBINING ELECTRONIC MONITORING WITH INHALED PHARMACOLOGICAL THERAPY TO MANAGE CARDIAC ARRHYTHMIAS INCLUDING ATRIAL FIBRILLATION

Disclosed herein are methods of treating cardiac arrhythmia with electronic monitoring in a timely manner. Also disclosed herein are systems for electronic monitoring of cardiac arrhythmia.

Compositions for treatment of attention deficit hyperactivity disorder

Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

Compositions for treatment of attention deficit hyperactivity disorder

Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

Silicone-containing acrylic polymers for transdermal drug delivery compositions

Described herein are silicone-containing acrylic polymers useful, for example, in transdermal drug delivery compositions, to methods of making and using them, to transdermal drug delivery compositions comprising them, and to methods of making and using such transdermal drug delivery compositions. The polymers are particular suitable for formulating amine drugs, such as amphetamine, methylphenidate, rivastigmine, paroxetine and clonidine.

Silicone-containing acrylic polymers for transdermal drug delivery compositions

Described herein are silicone-containing acrylic polymers useful, for example, in transdermal drug delivery compositions, to methods of making and using them, to transdermal drug delivery compositions comprising them, and to methods of making and using such transdermal drug delivery compositions. The polymers are particular suitable for formulating amine drugs, such as amphetamine, methylphenidate, rivastigmine, paroxetine and clonidine.

Hyaluronic acid and its use for treating venous insufficiency and varicose veins
09730887 · 2017-08-15 · ·

The present invention relates to an injectable aqueous viscous solution for treating varicose veins. It also relates to a catheter system with cannulas for vascular puncture with double or triple cut tip comprising, (i) an outer cannula (non-cutting element), a tube-like construction which is slightly flexible, (a) the tip zone being tapered to ease introduction, (b) the edges being optionally rounded to provide atraumatic advancement (c) optionally with a Luer-lock connector (ii) a hollow needle which is flexible and bendable (c) optionally with a transparent flashback chamber, wherein (d) the diameter of the needle is below the diameter of the catheter, wherein (iii) the needle and outer cannula are connected by a temporary lock to ensure the needle tip is fixed in adequate position outside the outer cannula outer cannula during skin puncture and introduction towards the target region.